Lacer is seeking to identify and develop innovative solutions that address the root cause of gingivitis by actively restoring oral microbiome balance (eubiosis), moving beyond traditional 'kill bacteria' strategies.
To be considered successful, proposals must demonstrate:
- A proven ability to shift the oral microbiome composition from a dysbiotic to a eubiotic state.
- A targeted reduction of key pathogenic species associated with gingivitis.
- The simultaneous increase or preservation of beneficial commensal bacteria to deliver more sustainable clinical outcomes.
While current gingivitis treatments primarily rely on broad bacterial reduction (antiseptics) or symptom control (anti-inflammatories), emerging science indicates that long-term oral health depends on precise microbiome modulation. Lacer aims to establish leadership in microbiome-based oral care by integrating this science into next-generation products, enabling new differentiated claims such as reversing early-stage gingivitis by targeting underlying imbalances.
Lacer is open to a range of collaborative business relationships, including:
- R&D contracts
- Licensing agreements
- Joint development partnerships (Open to companies, startups, and universities).
Must-Have Requirements
Maturity:The proposed solution must be at a Technology Readiness Level (TRL) of > 5.
Microbiome Modulation:Solutions must demonstrate selective antimicrobial activity in multispecies oral biofilm models, showing a reduction in periodontopathogenic bacteria and preservation of commensal bacteria.
Validation Method:Proof of a microbiome shift must be demonstrated using ex vivo oral-derived systems, such as saliva or plaque inoculum models, evaluated by 16S rRNA gene sequencing.
Biological Relevance:Technologies must show biological relevance, such as the reduction of pro-inflammatory markers, improved barrier function, tissue regeneration, or bacteremia risk reduction.
Format & Safety: Solutions must be safe for daily oral use and ensure compatibility with standard oral care formulations like toothpaste, mouthwash, or serums.
Regulatory Framework:The technology must strictly fit within cosmetic, medical device, or food supplement regulatory frameworks.
Geographical scope:Solutions must be commercially viable within Spain and the European Union, while Latin America is also recognized as an area of interest.
Proposals must explicitly detail the mechanism of action, type of microbiome modulation (selective, broad, or targeted), available scientific evidence, safety data, application feasibility in oral care, and the current development stage.
Complementary Innovations: The challenge is inclusive of potential tools from other industries, such as cosmetic tools, that could complement current products and enhance the microbiome-restoring efficacy.
Nice to have
We are looking for technologies at least capable of demonstrating efficacy in patients with Grade 2 gingivitis, ideally showing measurable improvements.
Discarded solutions
Possible solution areas
Lacer S.A is a pharmaceutical laboratory firmly committed to public health. Our research and services focus on improving people's well-being and quality of life.
Create your free account to connect with Lacer, S.A and thousands of other innovative organizations and professionals worldwide
Innovation Needs on Innoget are directly posted and managed by its members as well as evaluation of proposals. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help submitting your proposal or have questions regarding this Innovation Need?
Contact Innoget support
In the solution proposal submission form:
